Prior to its acquisition by Innomar Strategies, Ferg was a member of the Wyatt Health Management team for five years, where he started as a Market Access Manager. Since then, Ferg has been dedicated to developing his understanding of the technical and policy areas of importance to his clients. Ferg completed his Master’s degree in Economic Evaluation in 2014, and has put his qualifications to work as the company’s HTA expert. He has also received professional training in a variety of related subjects, ranging from database analysis to evidence synthesis, patient-reported outcomes and advanced modeling techniques.
In his current role as Director of Strategic Consulting, Ferg provides advice and insight directly to clients in both a leadership and technical capacity. Ferg has taken on increasingly significant leadership roles in successfully-completed projects across a wide variety of clinical areas. His work typically includes project leadership on full submission dossiers, lead authorship of primary documents, such as economic evaluations, clinical summaries, and budget impact analyses for submission to national and regional HTA agencies, and external stakeholder engagement. Ferg also trains clients in reimbursement, health technology assessment and pharmacoeconomics, and leads stakeholder insight research, including advisory boards and interviews with payer consultants and clinical leaders.
Ferg currently volunteers as the director of finance of the Canadian Association for Healthcare Reimbursement (CAHR), developing the profile of the organization, and participating in event-planning. Ferg has been closely involved in important new initiatives at CAHR, including the CAHR scholarship program for students in market access-related fields, and the creation of a new accreditation program for market access professionals, CMAP.
Agenda: Day 1 Oct 5, 2020
Agenda: Day 2 Oct 6, 2020
Panel Discussion: HEALTH ECONOMICS
PERSPECTIVE IS EVERYTHING – WHAT AND WHO SHOULD COUNT?
This session will explore the concept of a societal perspective vs a MOH perspective in economic evaluations. Should certain disease areas be assessed based on a societal perspective? The panel will explore this for rare diseases, Chronic diseases and Cancer.